



Statement from Novo Nordisk Canada

Re: FDA Issues Public Health Advisory Regarding Levemir® Insulin

Mississauga, ON (June 16, 2009) – On June 13, 2009 a U.S. press release announced that **vials** of Novo Nordisk Levemir® insulin previously reported as stolen in North Carolina have resurfaced at a Houston medical center. These stolen insulin vials may not have been properly stored or handled and product quality may be compromised.

Please note that Novo Nordisk does not market or sell Levemir® in vial format in Canada. At this time, no stolen vials of Levemir® insulin have been found in Canada. The Levemir® insulin sold and marketed in Canada is a 3 mL cartridge format that is inserted into a Novolin-Pen® delivery system. Insulin used in a vial format is administered with a syringe only and cannot be administered using a Novolin-Pen®.

The safety of our patients is of paramount concern and we encourage any Canadian who has questions about their Levemir® insulin to contact Novo Nordisk Canada Customer Care Centre at **1-800-465-4334** for further information.

Information about the stolen vials in the US

Three lots of 10 ml vials of insulin, marketed under the brand name Levemir® (insulin detemir [rDNA origin] injection), were taken in the original theft and identifiable by the following lot numbers: XZF0036, XZF0037, XZF0038.

A vial or vials of stolen insulin from lot XZF0037 was discovered this week at a medical centre in the Houston area. Insulin from these lots did not circulate through the normal Novo Nordisk distribution channel and therefore proper storage conditions for the insulin may not have been followed. Patients can locate the lot number on the side of the box of insulin or the side of the vial.